Crescent BiopharmaFRA:C68 18 EBIT per Share is €-9.12 as of Mar. 2026. GuruFocus rates FRA:C68 with a GF Score™ of 18/100. The stock has 2 warning signs investors should review. Among 1,173 Biotechnology companies, Crescent Biopharma ranks worse than 85251.41% on this metric.
Crescent Biopharma's EBIT per Share for the
three
months ended in Mar. 2026 was €-0.66.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €-9.12.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Crescent Biopharma's EBIT per Share or its related term are showing as below:
FRA:C68's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.4 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
Crescent Biopharma (FRA:C68) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Crescent Biopharma EBIT per Share Related Terms
Crescent Biopharma EBIT per Share Historical Data
* Premium members only.
The historical data trend for Crescent Biopharma's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-9.12
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crescent Biopharma (FRA:C68) has a EBIT per Share of €-9.12 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Crescent Biopharma and its competitors. According to the industry distribution chart, Crescent Biopharma ranks #999999 out of 1173 companies in the Biotechnology industry.
Is Crescent Biopharma's EBIT per Share too high?
Crescent Biopharma's current EBIT per Share is €-9.12. Based on the distribution chart, Crescent Biopharma ranks #999999 out of 1173 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Crescent Biopharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Crescent Biopharma's EBIT per Share compare to KYTX and ZURA?
According to the Biotechnology industry distribution chart, Crescent Biopharma ranks #999999 out of 1173 companies for EBIT per Share. This places Crescent Biopharma in the lower half of its industry. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Crescent Biopharma and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crescent Biopharma's current EBIT per Share is €-9.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescent Biopharma stock overvalued right now?
Crescent Biopharma (FRA:C68) has a current EBIT per Share of €-9.12. The current EBIT per Share is €-9.12. Crescent Biopharma's overall GF Score™ is 18/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Crescent Biopharma (FRA:C68), the current EBIT per Share is €-9.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
18GF Score
Get the complete analysis for FRA:C68
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:C68 has been successfully added to your 